Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Prostate Cancer

  Free Subscription


1 Am J Clin Oncol
1 Am J Surg Pathol
1 Anticancer Res
1 BMC Cancer
2 BMC Urol
2 Br J Cancer
1 Cancer
1 Cancer Lett
1 Eur Radiol
2 Int J Urol
3 J Magn Reson Imaging
1 J Nucl Med
4 J Urol
1 Nat Rev Urol
1 Oncogene
1 Oncol Rep
1 PLoS One
2 Prostate

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Clin Oncol

  1. SOLIMAN L, De Souza A, Srinivasan P, Danish M, et al
    The Role of BCL-2 Proteins in the Development of Castration-resistant Prostate Cancer and Emerging Therapeutic Strategies.
    Am J Clin Oncol. 2021 May 17. pii: 00000421-900000000-98561.
    PubMed         Abstract available

    Am J Surg Pathol

  2. VAN DER KWAST TH, van Leenders GJ, Berney DM, Delahunt B, et al
    ISUP Consensus Definition of Cribriform Pattern Prostate Cancer.
    Am J Surg Pathol. 2021 May 13. pii: 00000478-900000000-97205.
    PubMed         Abstract available

    Anticancer Res

  3. IINUMA K, Kawakami K, Mizutani K, Fujita Y, et al
    miRNA-93 in Serum Extracellular Vesicles Before and After Low Dose Rate Prostate Brachytherapy.
    Anticancer Res. 2021;41:2411-2418.
    PubMed         Abstract available

    BMC Cancer

  4. SHAH S, Beckmann K, Van Hemelrijck M, Challacombe B, et al
    Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.
    BMC Cancer. 2021;21:573.
    PubMed         Abstract available

    BMC Urol

  5. NYK L, Tayara O, Zabkowski T, Kryst P, et al
    The role of mpMRI in qualification of patients with ISUP 1 prostate cancer on biopsy to radical prostatectomy.
    BMC Urol. 2021;21:82.
    PubMed         Abstract available

  6. YANG L, Lee JA, Heer E, Pernar C, et al
    One-year urinary and sexual outcome trajectories among prostate cancer patients treated by radical prostatectomy: a prospective study.
    BMC Urol. 2021;21:81.
    PubMed         Abstract available

    Br J Cancer

  7. CRISTOBAL I, Santos A, Rubio J, Rojo F, et al
    Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition".
    Br J Cancer. 2021 May 19. pii: 10.1038/s41416-021-01433.

  8. WOKOLORCZYK D, Kluzniak W, Stempa K, Rusak B, et al
    PALB2 mutations and prostate cancer risk and survival.
    Br J Cancer. 2021 May 18. pii: 10.1038/s41416-021-01410.
    PubMed         Abstract available


  9. COLE AP, Herzog P, Iyer HS, Marchese M, et al
    Racial differences in the treatment and outcomes for prostate cancer in Massachusetts.
    Cancer. 2021 May 17. doi: 10.1002/cncr.33564.
    PubMed         Abstract available

    Cancer Lett

  10. LLOPIZ D, Ruiz M, Silva L, Reparaz D, et al
    Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.
    Cancer Lett. 2021;499:279-289.
    PubMed         Abstract available

    Eur Radiol

  11. DELLI PIZZI A, Mastrodicasa D, Marchioni M, Primiceri G, et al
    Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach.
    Eur Radiol. 2020 Nov 19. pii: 10.1007/s00330-020-07473.
    PubMed         Abstract available

    Int J Urol

  12. INOUE T, Yoshimura K, Terada N, Tsukino H, et al
    Prostate-specific antigen density during dutasteride treatment for 1 year predicts the presence of prostate cancer in benign prostatic hyperplasia after the first negative biopsy (PREDICT study).
    Int J Urol. 2021 May 18. doi: 10.1111/iju.14590.
    PubMed         Abstract available

  13. WURNSCHIMMEL C, Wenzel M, Colla Ruvolo C, Nocera L, et al
    Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups.
    Int J Urol. 2021 May 15. doi: 10.1111/iju.14595.
    PubMed         Abstract available

    J Magn Reson Imaging

  14. SCHIEDA N, Lim CS, Zabihollahy F, Abreu-Gomez J, et al
    Quantitative Prostate MRI.
    J Magn Reson Imaging. 2020 May 15. doi: 10.1002/jmri.27191.
    PubMed         Abstract available

  15. LEE CM, Park KJ, Kim MH, Kim JK, et al
    Ancillary imaging and clinical features for the characterization of prostate lesions: A proposed approach to reduce false positives.
    J Magn Reson Imaging. 2020 Dec 29. doi: 10.1002/jmri.27491.
    PubMed         Abstract available

  16. SCHAAPMAN JJ, Coenraad MJ, Lamb HJ
    Response to letter: Multiparametric magnetic resonance imaging in patients with nonalcoholic fatty liver disease.
    J Magn Reson Imaging. 2021 Jan 12. doi: 10.1002/jmri.27510.

    J Nucl Med

  17. CALAIS J, Gafita A, Eiber MR, Armstrong WR, et al
    Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with (177)Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.
    J Nucl Med. 2021 May 20. pii: jnumed.121.261982. doi: 10.2967/jnumed.121.261982.
    PubMed         Abstract available

    J Urol

  18. KLEIN EA
    Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2. Reply.
    J Urol. 2021 May 17:101097JU0000000000001884. doi: 10.1097/JU.0000000000001884.

  19. MARSHALL CH, Chen Y, Kuo C, Cullen J, et al
    Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
    J Urol. 2021 May 18:101097JU0000000000001797. doi: 10.1097/JU.0000000000001797.
    PubMed         Abstract available

  20. MACDONALD S, Matos A, Wambier C
    Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2. Letter.
    J Urol. 2021 May 17:101097JU0000000000001883. doi: 10.1097/JU.0000000000001883.

    Urological Oncology: Prostate Cancer.
    J Urol. 2021 May 17:101097JU0000000000001865. doi: 10.1097/JU.0000000000001865.

    Nat Rev Urol

  22. LOKESHWAR SD, Klaassen Z, Saad F
    Treatment and trials in non-metastatic castration-resistant prostate cancer.
    Nat Rev Urol. 2021 May 17. pii: 10.1038/s41585-021-00470.
    PubMed         Abstract available


  23. LEE HC, Ou CH, Huang YC, Hou PC, et al
    Correction: YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer.
    Oncogene. 2021 May 19. pii: 10.1038/s41388-021-01836.

    Oncol Rep

  24. LI JM, Lee S, Zafar R, Shin E, et al
    Sodium bicarbonate transporter NBCe1 regulates proliferation and viability of human prostate cancer cells LNCaP and PC3.
    Oncol Rep. 2021;46.
    PubMed         Abstract available

    PLoS One

  25. SAIDOVA AA, Potashnikova DM, Tvorogova AV, Paklina OV, et al
    Myosin 1C isoform A is a novel candidate diagnostic marker for prostate cancer.
    PLoS One. 2021;16:e0251961.
    PubMed         Abstract available


  26. FERRARIS F, Yaber F, Smith AB, Barreiro D, et al
    The end of "very low risk" in localized prostate cancer?
    Prostate. 2021 May 19. doi: 10.1002/pros.24168.

  27. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.
    Prostate. 2021 May 19. doi: 10.1002/pros.24169.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.